Zak Designs launches Snow White products
SPOKANE, Wash. Zak Designs on Monday announced the launch of a line of products that showcase Snow White and her seven friends to correspond with the fall release of Snow White and the Seven Dwarfs from the Disney Vault on Blu-ray hi-def and DVD.
The products feature traditional artwork.
Study suggests eating broccoli daily may be good for gut
BALTIMORE, Md. A small, pilot study in 50 people in Japan suggested that eating 2.5 oz. of broccoli sprouts daily for two months may confer some protection against a rampant stomach bug that causes gastritis, ulcers and even stomach cancer.
Citing their new “demonstration of principle” study, a Johns Hopkins researcher and an international team of scientists caution that eating sprouts containing sulforaphane did not cure infection by the bacterium Helicobacter pylori. And they do not suggest that eating this or any amount of broccoli sprouts will protect anyone from stomach cancer or cure GI diseases.
However, the study does show that eating a daily dose of broccoli sprouts reduced by more than 40% the level of HpSA, a highly specific measure of the presence of components of H. pylori shed into the stool of infected people. There was no HpSA level change in control subjects who ate alfalfa sprouts. The HpSA levels returned to pretreatment levels eight weeks after people stopped eating the broccoli sprouts, suggesting that although they reduce H. pylori colonization, they do not eradicate it.
“The highlight of the study is that we identified a food that, if eaten regularly, might potentially have an effect on the cause of a lot of gastric problems and perhaps even ultimately help prevent stomach cancer,” stated Jed Fahey, an author of the paper who is a nutritional biochemist in the Lewis B. and Dorothy Cullman Cancer Chemoprotection Center at the Johns Hopkins University School of Medicine. “Broccoli sprouts have a much higher concentration of sulforaphane than mature heads,” Fahey explained, adding that further investigation is needed to affirm the results of this clinical trial and move the research forward. The study, published April 6 in Cancer Prevention Research, builds on earlier test-tube and mouse studies at Johns Hopkins and elsewhere about the potential value of sulforaphane, a naturally occurring biochemical found in relative abundance in fresh broccoli sprouts.
“I like them,” Fahey said. “I eat them all the time, but not every day. Variety is the spice of life: I eat blueberries on the other days.”
Fucopure’s advertising claims forwarded to FTC
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday referred advertising published by Nutraceuticals International for Fucopure to the Federal Trade Commission for further review.
Nutraceuticals declined to participate in an NAD proceeding, following a challenge to its advertising by P.L. Thomas, a competing maker of dietary supplements.
NAD, the advertising industry’s self-regulatory forum, asked the advertiser to provide substantiation for disease claims that tout FucoPure as a “totally new, totally innovative approach to combating obesity, hyperlipidemia and Type II diabetes.”
Under Food and Drug Administration regulations, no dietary supplement can be purported to treat, mitigate or prevent a disease, which would include obesity, hyperlipidemia and diabetes.
NAD also requested substantiation for weight-loss claims that state FucoPure was proven in the “First U.S. human clinical trial to show the ability of a physician strength Fucoxanthin extract to significantly reduce body weight, percent body fat …” and strong superiority and exclusivity claims, including claims that state that FucoPure is “The Only Clinical Strength Fucoxanthin 10% Extract.”
The advertiser failed to respond to NAD’s initial inquiry, but responded through its attorney after receiving NAD’s second letter. At that time, the advertiser, through its attorney, requested an extension as a professional courtesy, which was granted. The advertiser failed to file a response on the agreed upon date, and despite continued outreach from NAD, has refused to participate.
Given the advertiser’s failure to provide a substantive response, pursuant to Section 2.9 of the NAD/NARB Procedures, NAD will refer this matter to the FTC and FDA for possible law enforcement action.